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Experimental verification of a traceback phenomenon in prion
infection
Abstract
The clinicopathological phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD) correlate with the
allelotypes (M or V) of the polymorphic codon 129 of the human prion protein (PrP) gene and the
electrophoretic mobility patterns of abnormal prion protein (PrP(Sc)). Transmission of sCJD prions to
mice expressing human PrP with a heterologous genotype (referred to as cross-sequence transmission)
results in prolonged incubation periods. We previously reported that cross-sequence transmission can
generate a new prion strain with unique transmissibility designated as a traceback phenomenon. To
verify experimentally the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into mice
expressing human PrP with the 129M/M genotype. These 129M/M mice showed altered neuropathology
and a novel PrP(Sc) type after a long incubation period. We then passaged the brain homogenate from
the 129M/M mouse inoculated with sCJD-VV2 prions into further 129M/M or 129V/V mice. Despite
cross-sequence transmission, 129V/V mice were highly susceptible to these prions compared to the
129M/M mice. The neuropathology and PrP(Sc) type of the 129V/V mice inoculated with the 129M/M
mouse-passaged sCJD-VV2 prions were identical to those of the 129V/V mice inoculated with
sCJD-VV2 prions. Moreover, we generated for the first time type 2 PrP(Sc)-specific antibody in
addition to type 1 PrP(Sc)-specific antibody and discovered that drastic changes in the PrP(Sc)
subpopulation underlie the traceback phenomenon. Here we report the first direct evidence of the
traceback in prion infection.
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 2 
ABSTRACT 1 
The clinicopathological phenotypes of sporadic Creutzfeldt-Jakob disease (sCJD) correlate with the 2 
allelotypes (M or V) of the polymorphic codon 129 of the human prion protein (PrP) gene and the 3 
electrophoretic mobility patterns of abnormal prion protein (PrP
Sc
). Transmission of sCJD prions to mice 4 
expressing human PrP with a heterologous genotype (referred to as cross-sequence transmission) results 5 
in prolonged incubation periods. We previously reported that cross-sequence transmission can generate a 6 
new prion strain with unique transmissibility designated as a traceback phenomenon. To verify 7 
experimentally the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into mice 8 
expressing human PrP with the 129M/M genotype. These 129M/M mice showed altered 9 
neuropathology and a novel PrP
Sc
 type after a long incubation period. We then passaged the brain 10 
homogenate from the 129M/M mouse inoculated with sCJD-VV2 prions into further 129M/M or 11 
129V/V mice. Despite cross-sequence transmission, 129V/V mice were highly susceptible to these 12 
prions compared to the 129M/M mice. The neuropathology and PrP
Sc
 type of the 129V/V mice 13 
inoculated with the 129M/M mouse-passaged sCJD-VV2 prions were identical to those of the 129V/V 14 
mice inoculated with sCJD-VV2 prions. Moreover, we generated for the first time type 2 PrP
Sc
-specific 15 
antibody in addition to type 1 PrP
Sc
-specific antibody and discovered that drastic changes in the PrP
Sc
 16 
subpopulation underlie the traceback phenomenon. Here we report the first direct evidence of the 17 
traceback in prion infection. 18 
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 3 
INTRODUCTION 1 
  Creutzfeldt-Jakob disease (CJD) is a lethal transmissible neurodegenerative disease caused by an 2 
abnormal isoform of prion protein (PrP
Sc
), which is converted from the normal cellular isoform (PrP
C
) (1, 3 
23). The genotype (M/M, M/V, or V/V) at polymorphic codon 129 of the human prion protein (PrP) 4 
gene and the type (type 1 or type 2) of PrP
Sc
 in the brain are major determinants of the 5 
clinicopathological phenotypes of sporadic CJD (sCJD) (15-18). Type 1 and type 2 PrP
Sc
 are 6 
distinguishable according to the size of the proteinase K-resistant core of PrP
Sc
 (PrP
res
) (21 and 19 kDa, 7 
respectively), reflecting differences in the proteinase K-cleavage site (at residues 82 and 97, respectively) 8 
(15, 18). According to this molecular typing system, sCJD can be classified into six subgroups (MM1, 9 
MM2, MV1, MV2, VV1, or VV2). 10 
  The homology of the PrP gene between inoculated animals and the inoculum determines the 11 
susceptibility to prion infection. Transmission of sCJD prions to mice expressing human PrP with a 12 
non-homologous genotype (referred to as cross-sequence transmission) results in a relatively long 13 
incubation period (10, 12). Meanwhile, the cross-sequence transmission can generate a new prion strain. 14 
Transmission of sCJD-VV2 prions to mice expressing human PrP with the 129M/M genotype generates 15 
unusual PrP
res
 intermediate in size between type 1 and type 2 (10). We have designated this unusual 16 
PrP
res
 with an upward size shift (Sh+) from the inoculated type 2 template as MM[VV2]2
Sh+
 PrP
res
: host 17 
genotype [inoculated prions] type of generated PrP
res
. 18 
  Similar to the MM[VV2]2
Sh+
 PrP
res
, the intermediate-sized PrP
res
 has been observed in the plaque-type 19 
of dura mater graft-associated CJD (p-dCJD) (10, 13). Furthermore, a transmission study using p-dCJD 20 
prions revealed that PrP-humanized mice with the 129V/V genotype were highly susceptible to p-dCJD 21 
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 4 
prions despite cross-sequence transmission (10). In addition, these 129V/V mice inoculated with p-dCJD 1 
prions produced type 2 PrP
res 
(10). These findings suggest that p-dCJD could be caused by 2 
cross-sequence transmission of sCJD-VV2 prions to individuals with the 129M/M genotype. We have 3 
designated these phenomena as “traceback”. The traceback phenomenon was discovered for the first 4 
time by a transmission study using variant CJD (vCJD) prions (2). Mice expressing bovine PrP were 5 
highly susceptible to vCJD prions because vCJD was caused by cross-sequence transmission of bovine 6 
spongiform encephalopathy prions to human. These findings suggest that a traceback study can be a 7 
powerful tool to identify the origin of prions (2, 10, 11). However, the traceback phenomenon has not 8 
been verified experimentally despite the abundant circumstantial evidence described above. 9 
  To verify the traceback of sCJD-VV2 prions, we inoculated sCJD-VV2 prions into PrP-humanized 10 
mice with the 129M/M genotype as an experimental model of p-dCJD. Thereafter, we inoculated these 11 
MM[VV2]2
Sh+
 prions into PrP-humanized mice with the 129M/M or 129V/V genotype, and compared 12 
the incubation period, neuropathology, and the type of PrP
res
 in the brain. Here we report the first direct 13 
evidence of the traceback in prion infection. 14 
 15 
MATERIALS AND METHODS 16 
Production of PrP
res
 type-specific polyclonal antibodies 17 
A synthetic peptide corresponding to human PrP 82-98 was used as the immunogen for type 1 18 
PrP
res
-specific antibody Tohoku 1 because residues 82-96 were retained in type 1 PrP
res
 but not in type 2 19 
PrP
res
 after proteinase K-digestion (18). For type 2 PrP
res
-specific antibody Tohoku 2, a short synthetic 20 
peptide corresponding human PrP 97-103 was used as the immunogen because the length of the 21 
 at Universitaet Zuerich on January 28, 2010 
jvi.asm.org
D
ow
nloaded from
 
 5 
immunogen peptide is critical for the production of proteolytic cleavage site-specific polyclonal 1 
antibodies (25, 26). Cysteine residues were added to the C-terminus of the each peptide and was utilized 2 
for conjugation to bovine thyroglobulin via EMCS (N-(6-Maleimidocaproyloxy)succinimide) (Dojin). 3 
For the initial injection, 100 μg of conjugates were emulsified in complete Freund’s adjuvant and 4 
subcutaneously injected into rabbits. For the boosting injections, 100 μg of conjugates were emulsified in 5 
incomplete Freund’s adjuvant and were subcutaneously injected on days 7, 21, 35, 49, 63, 84, and day 6 
91. At day 98, the rabbits were sacrificed and sera were collected. Antibodies were purified by affinity 7 
chromatography using the immunogen peptides. Another type 1 PrP
res
-specific monoclonal antibody, 8 
POM2, reacts with repeated octapeptide epitopes 59-65, 67-73, 75-81, and 83-89 of human and murine 9 
PrP (21, 22). 10 
 11 
Production of knock-in mice and transgenic mice 12 
The production of knock-in mice expressing human PrP with 129M/M (Ki-Hu129M/M) and 13 
Ki-Hu129V/V mice has been reported previously (2). Ki-Hu129M/M mice and knock-in mice 14 
expressing human PrP with 129M/M and 4 octapeptide repeats (Ki-Hu129M4R/M4R) were crossed with 15 
transgenic mice expressing human PrP with 129M (Tg-Hu129M) and Tg-Hu129M4R, respectively (10). 16 
The expression levels of human PrP in the brains from Tg+Ki-Hu129M/M and Tg+Ki-Hu129M4R/M4R 17 
were 1.2X and 9.8X, respectively, the levels observed in Ki-Hu129M/M mice. 18 
 19 
Human brain inocula 20 
Brain tissues were obtained at autopsy from CJD patients after receiving informed consent for research 21 
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 6 
use. The diagnosis of CJD and the type of PrP
Sc
 were confirmed by neuropathological examination, 1 
PrP
Sc
 immunohistochemistry and western blotting as described (7, 27). The genotype and the absence of 2 
mutations in the open reading frame of the PrP gene were determined by sequence analysis (8). The CJD 3 
cases selected for the transmission studies were typical of the sCJD-MM1 and sCJD-VV2 subgroups. In 4 
the sCJD-VV2 case (AK), the plaque-type PrP deposition in the brain and the absence of periodic 5 
synchronous discharges on electroencephalogram were confirmed. More detailed information of the 6 
patient was reported previously (4). sCJD-MM1 (H3) and sCJD-VV2 (AK) showed the same 7 
transmissibilities to PrP-humanized mice as those of the other sCJD-MM1 and sCJD-VV2 isolates, 8 
respectively (27).  9 
 10 
Transmission experiments 11 
Human brain homogenates (10%) and mouse brain homogenates (10%) were prepared as described (9). 12 
Intracerebral transmission was performed using 20 µl of the homogenates (27). The inoculated mice 13 
were sacrificed after the onset of disease, and their brains were immediately frozen or fixed in 10% 14 
buffered formalin. 15 
 16 
Immunohistochemistry 17 
Formalin-fixed mouse brains were treated with 60% formic acid for 1 hour to inactivate the infectivity 18 
and embedded in paraffin. Tissue sections were pretreated by hydrolytic autoclaving before PrP 19 
immunohistochemistry (7). The PrP-N antiserum was used as the primary antibody (6). Goat-anti-rabbit 20 
immunoglobulins polyclonal antibody labeled with the peroxidase-conjugated dextran polymer, 21 
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 7 
EnVision+ (DakoCytomation) was used as the secondary antibody. 1 
 2 
Expression of Glutathione S-transferase (GST)-fusion recombinant PrP 3 
The open reading frame of the human PrP gene was amplified by PCR with human DNA. The amplified 4 
fragment was cloned into pBluescript plasmid (Stratagene). With the plasmid construct, N-terminally or 5 
C-terminally truncated human PrP gene fragments were amplified by PCR. The primers used for the 6 
amplification are shown in Table 1. These primers introduced BamH I sites at the 5’ end of the fragments 7 
and Xho I sites at the 3’ end of the fragments. The amplified fragments were cloned into pGEM-T Easy 8 
plasmid (Promega). After digestion with BamH I and Xho I, the fragments were inserted into the BamH 9 
I/Xho I sites of the expression vector pGEX-4T-1 (GE Healthcare). Escherichia coli BL21 (DE3) were 10 
transformed with the pGEX-4T-1 plasmid constructs, and GST- fusion recombinant PrP fragments were 11 
purified using glutathione sepharose 4B beads (GE Healthcare) according to the manufacturer’s 12 
instructions. GST-fusion recombinant PrP fragments were subjected to 13% SDS-PAGE and western 13 
blotting. 14 
 15 
Enzyme-linked immunosorbent assay (ELISA) 16 
Synthetic peptides corresponding to human PrP 97-103 and 93-103 were used as the antigens. Plates were 17 
individually coated with 50 ng/50 μl /well antigen or with 0.1% bovine serum albumin (BSA). The 18 
polyclonal antibody Tohoku 2 was serially diluted and added to each well as the primary antibody. 19 
Goat-anti-rabbit IgG Fab’ fraction labeled with horseradish peroxidase was used as the secondary antibody. 20 
The color was developed with ο-phenylenediamine. 21 
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 8 
 1 
Western blotting 2 
PrP
Sc
 was extracted from mouse brains with collagenase treatment as described (5) with some 3 
modifications. Samples were subjected to 13% SDS-PAGE and western blotting as described (2). The 3F4 4 
monoclonal antibody (Signet Laboratories), PrP-N (Immuno-Biological Laboratories), PrP-C 5 
(Immuno-Biological Laboratories), POM2, Tohoku 1, and Tohoku 2 were used as the primary antibodies. 6 
Anti-mouse EnVision+ and anti-rabbit EnVision+ were used as the secondary antibodies. The signal 7 
intensities of the western blots were quantified with Quantity One software using an imaging device 8 
VersaDoc 5000 (Bio-Rad Laboratories). 9 
 10 
Statistical analysis 11 
Incubation times and signal intensities of PrP
res
 bands are expressed as mean ± SEM. 12 
 13 
RESULTS 14 
Transmission of MM[VV2]2
Sh+
 prions to PrP-humanized mice with the 129M/M or 129V/V 15 
genotype 16 
To verify the traceback of sCJD-VV2 prions, we performed intracerebral inoculation of a brain 17 
homogenate from a sCJD-VV2 patient into Tg+Ki-Hu129M/M mice. Thereafter, we performed the 18 
second passage of the brain homogenate from Tg+Ki-Hu129M/M mouse inoculated with sCJD-VV2 19 
prions (MM[VV2]2
Sh+
 prions: host genotype [inoculated prions] type of generated PrP
res
). Since 20 
Tg+Ki-Hu129M/M mice were established before the Ki-Hu129M/M mice were produced, we used 21 
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 9 
them in the primary transmission of sCJD-VV2 prions. The data of the primary transmission were 1 
already reported previously (10). The mean incubation time of Tg+Ki-Hu129M/M mice inoculated with 2 
sCJD-VV2 prions was 723 ± 79 days (number of diseased animals / number of inoculated animals = 3 
4/4) (Table 2). In the second passage, we inoculated intracerebrally the MM[VV2]2
Sh+
 prions into 4 
Ki-Hu129M/M mice or Ki-Hu129V/V mice. Ki-Hu129M/M mice inoculated with MM[VV2]2
Sh+ 
5 
prions showed long incubation times of 685 ± 17 days (6/6). By contrast, the mean incubation time of 6 
Ki-Hu129V/V mice inoculated with MM[VV2]2
Sh+ 
prions was shortened to 309 ± 3 days (7/7). In spite 7 
of cross-sequence transmission, the mean incubation time of Ki-Hu129V/V mice was much shorter than 8 
that of Ki-Hu129M/M mice. Immunohistochemical analysis of the brains from Tg+Ki-Hu129M/M 9 
mice inoculated with sCJD-VV2 prions showed large plaque-type PrP deposits spread throughout the 10 
cerebral grey matter and thalamus (Fig. 1). Ki-Hu129M/M mice inoculated with MM[VV2]2
Sh+ 
prions 11 
showed similar patterns of PrP deposition to those of Tg+Ki-Hu129M/M mice inoculated with 12 
sCJD-VV2 prions. By contrast, Ki-Hu129V/V mice inoculated with MM[VV2]2
Sh+ 
prions showed 13 
diffuse synaptic-type PrP deposits in the grey matter and small plaque-type deposits restricted to within 14 
the cerebral white matter. These patterns of PrP deposition were identical to those of Ki-Hu129V/V mice 15 
inoculated with sCJD-VV2 prions. Thus, we confirmed that Ki-Hu129V/V mice were highly 16 
susceptible to MM[VV2]2
Sh+ 
prions that originated from sCJD-VV2 prions, and that the neuropathology 17 
of Ki-Hu129V/V mice inoculated with MM[VV2]2
Sh+
 prions was identical to that of the Ki-Hu129V/V 18 
mice inoculated with the parental sCJD-VV2 prions. 19 
 20 
Characterization of PrP
res
 in the mouse brains using PrP
res
 type-specific antibodies 21 
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 10 
Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 prions produced unusual PrP
res
 with an upward 1 
size shift from the inoculated type 2 template (10). To characterize these type 2
Sh+ 
PrP
res
, we produced 2 
PrP
res
 type-specific antibodies. Type 1 PrP
res
-specific polyclonal antibody Tohoku 1 reacted with epitopes 3 
located between residues 82 and 96 of human PrP (Fig. 2). Type 2 PrP
res
-specific polyclonal antibody 4 
Tohoku 2 reacted with a synthetic peptide corresponding to human PrP 97-103 (the immunogen peptide) 5 
but not with peptide 93-103 (Fig. 3). The amino goup at the N-terminus of the immunogen peptide 6 
might constitute an essential part of the epitopes for Tohoku 2 as reported in other proteolytic cleavage 7 
site-specific antibodies (25, 26). Therefore, Tohoku 1 should specifically detect type 1 PrP
res
, and Tohoku 8 
2 should specifically detect the N-terminal cleavage site of type 2 PrP
res
 after proteinase K digestion (Fig. 9 
4A).  10 
  Firstly, with these PrP
res
 type-specific antibodies, we performed western blot analysis of the PrP
res
 in 11 
the human brain inocula used in this transmission study (Fig. 4B). In addition to the newly generated 12 
type-specific antibodies, we used the monoclonal antibody POM2, which also specifically detects type 1 13 
PrP
res
 (Fig. 2) (21), as a reference antibody. Conventional typing of PrP
res
 using monolconal antibody 14 
3F4, which detects all PrP
res
 types, showed only a single PrP
res
 type in the brain of a sCJD-MM1 patient 15 
or in that of a sCJD-VV2 patient. With the PrP
res
 type-specific antibodies, however, small amounts of 16 
POM2/Tohoku 1-reactive subpopulations were observed in the sCJD-VV2 brain (Fig. 4B, bar graphs). 17 
The mean signal intensities of PrP
res
 in the sCJD-MM1 brain were assigned as 100 / mm² in each 18 
experiment using 3F4, POM2, or Tohoku 1 (n = 3). In the western blot analysis using 3F4, the mean 19 
signal intensities of PrP
res
 in the sCJD-VV2 brain were 224 / mm² (white bars). By contrast, the signal 20 
intensities of POM2/Tohoku 1-reactive PrP
res
 bands in the sCJD-VV2 brain were 12 / mm² (hatched bar) 21 
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 11 
and 48 / mm² (grey bar), respectively. Thus, using type 1 PrP
res
-specific antibody, the sCJD-VV2 brain 1 
contained minority subpopulations that could be detected by type 1 PrP
res
-specific antibodies as reported 2 
previously (21, 28). The sizes of POM2/Tohoku 1-reactive bands were smaller than those of type 1 PrP
res
 3 
in the sCJD-MM1 brain. Thus, POM2 and Tohoku 1 could detect the intermediate-sized PrP
res
 in 4 
addition to type 1 PrP
res
. Furthermore, trace amounts of the Tohoku 2-reactive subpopulation were 5 
observed in the sCJD-MM1 brain (Fig. 4B, black bar). The mean signal intensities of PrP
res
 in the 6 
sCJD-VV2 brain were assigned as 100 / mm² in each experiment using Tohoku 2 (n = 3). The mean 7 
signal intensities of Tohoku 2-reactive PrP
res
 bands in the sCJD-MM1 brain were 2 / mm². Thus, using 8 
type 2 PrP
res
-specific antibody, the minority type 2 PrP
res
 subpopulation could be detected even in the 9 
sCJD-MM1 brain. 10 
  Secondly, we performed western blot analysis of PrP
res
 in the mouse brains using the PrP
res
 11 
type-specific antibodies. Western blot analysis using 3F4 showed that Tg+Ki-Hu129M/M mice 12 
inoculated with sCJD-VV2 prions produced type 2
Sh+
 PrP
res
 that was located between type 1 PrP
res
 from 13 
Ki-Hu129M/M mice inoculated with sCJD-MM1 prions and type 2 PrP
res
 from Ki-Hu129V/V mice 14 
inoculated with sCJD-VV2 prions (Fig. 4C) (10). These PrP
res
 were probed with type-specific antibodies 15 
Tohoku 1, Tohoku 2, or POM2. The brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 16 
prions contained POM2/Tohoku 1-reactive PrP
res
 subpopulations of which the sizes were smaller than 17 
those of type 1 PrP
res
 from Ki-Hu129M/M inoculated with sCJD-MM1 prions. However, the signal 18 
intensities of these POM2/Tohoku 1-reactive bands were apparently decreased compared to those 19 
detected by 3F4 (Fig. 4C, bar graphs). The mean signal intensities of PrP
res
 from Ki-Hu129M/M mice 20 
inoculated with sCJD-MM1 prions were assigned as 100 / mm² in each experiment using 3F4, POM2, 21 
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 12 
or Tohoku 1 (n = 4). In the brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 prions, the 1 
mean signal intensities of 3F4-reactive PrP
res
 bands were 154 / mm² (white bars). However, the mean 2 
signal intensities of POM2/Tohoku 1-reactive PrP
res
 bands were 34 / mm² (hatched bar) and 113 / mm² 3 
(grey bar), respectively. Since the epitopes for Tohoku 1 were located more at the C-terminal compared 4 
with that of POM2 (Fig. 2), the signal intensities of Tohoku 1-reactive bands might be higher than those 5 
of POM2-reactive bands. Thus, the brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 6 
prions contained the intermediate-sized PrP
res
, but certain subpopulations that could not be detected by 7 
POM2 or Tohoku 1 must also have been present. The Tohoku 2-reactive subpopulation was not 8 
observed in Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 prions or Ki-Hu129M/M mice 9 
inoculated with sCJD-MM1 prions (Fig. 4C, black bars). The mean signal intensities of PrP
res
 from 10 
Ki-Hu129V/V mice inoculated with sCJD-VV2 prions were assigned as 100 / mm² in each experiment 11 
using Tohoku 2 (n = 4). The brains from Ki-Hu129V/V mice inoculated with sCJD-VV2 prions 12 
contained small amounts of POM2/Tohoku 1-reactive subpopulations in addition to the Tohoku 13 
2-reactive majority subpopulation. Thus, in the cross-sequence transmission of sCJD-VV2 prions to 14 
Tg+Ki-Hu129M/M mice, POM2/Tohoku 1-reactive subpopulations were increased, whereas the 15 
Tohoku 2 reactive-subpopulation was decreased. Therefore, the upward size shift from type 2 to type 16 
2
Sh+
 in the western blot analysis using 3F4 reflected the shift of the majority PrP
res
 subpopulation from 17 
the Tohoku 2-reactive subpopulation to the POM2/Tohoku 1-reactive subpopulation. 18 
  In the second passage of the brain homogenate from Tg+Ki-Hu129M/M mouse inoculated with 19 
sCJD-VV2 prions (MM[VV2]2
Sh+
 prions: host genotype [inoculated prions] type of generated PrP
res
), 20 
Ki-Hu129M/M mice inoculated with MM[VV2]2
Sh+ 
prions produced the intermediate-sized PrP
res
 that 21 
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 13 
were identical in size to parental MM[VV2]2
Sh+ 
prions when probed with 3F4 (Fig. 4C). Similar to the 1 
brains from Tg+Ki-Hu129M/M mice inoculated with sCJD-VV2 prions, the brains from 2 
Ki-Hu129M/M mice inoculated with MM[VV2]2
Sh+ 
prions contained POM2/Tohoku 1-reactive 3 
subpopulations but not the Tohoku 2-reactive subpopulation. In the brains from Ki-Hu129M/M mice 4 
inoculated with MM[VV2]2
Sh+
 prions, the mean signal intensities of 3F4, POM2, and Tohoku 1-reactive 5 
PrP
res
 bands were 176 / mm² (white bars), 85 / mm² (hatched bar), and 139 / mm² (grey bar), respectively. 6 
Meanwhile, western blot analysis using 3F4 showed that Ki-Hu129V/V mice inoculated with 7 
MM[VV2]2
Sh+
 prions produced type 2 PrP
res
, i.e., the intermediate-sized PrP
res
 reverted to type 2 when 8 
MM[VV2]2
Sh+ 
prions were transmitted to Ki-Hu129V/V mice. Moreover, in the traceback transmission 9 
of MM[VV2]2
Sh+ 
prions to Ki-Hu129V/V mice, POM2/Tohoku 1-reactive subpopulations were 10 
decreased, whereas the Tohoku 2 reactive-subpopulation predominated. In the brains from 11 
Ki-Hu129V/V mice inoculated with MM[VV2]2
Sh+
 prions, the mean signal intensities of 3F4, POM2, 12 
and Tohoku 1-reactive PrP
res
 bands were 179 / mm² (white bars), 13 / mm² (hatched bar), and 43 / mm² 13 
(grey bar), respectively, whereas the mean signal intensities of Tohoku 2-reactive PrP
res
 bands were 159 / 14 
mm² (black bar). Thus, PrP
res
 type-specific antibodies revealed that cross-sequence transmission of 15 
sCJD-VV2 prions generated a new prion strain (MM[VV2]2
Sh+
 prions) with an altered proportion of 16 
PrP
res
 subpopulations, and that the altered proportion reverted to the original proportion through the 17 
traceback transmission to Ki-Hu129V/V mice. 18 
 19 
Traceback study of p-dCJD prions reevaluated with the PrP
res
 type-specific antibodies 20 
We reported previously that p-dCJD prions showed the intermediate-sized PrP
res
, and that Ki-Hu129V/V 21 
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 14 
mice inoculated with p-dCJD prions showed accumulation of type 2 PrP
res
 (10). To characterize these 1 
PrP
res
 in the brains from PrP-humanized mice inoculated with p-dCJD prions, we performed western 2 
blot analysis using PrP
res
 type-specific antibodies (Fig. 5). Since Tg+Ki-Hu129M4R/M4R mice were 3 
already established before the Ki-Hu129M/M mice were produced, we used them in the traceback study 4 
of p-dCJD or np-dCJD prions. Subsequently, we confirmed that Tg+Ki-Hu129M4R/M4R, 5 
Ki-Hu129M/M, and Tg+Ki-Hu129M/M mice produced PrP
res
 identical in size in the transmission 6 
studies using various CJD prions (10). POM2/Tohoku 1-reactive subpopulations existed in the brains 7 
from Tg+Ki-Hu129M4R/M4R mice inoculated with p-dCJD prions, but the signal intensities were 8 
apparently decreased compared to those detected by 3F4 (Fig. 5, bar graphs). The mean signal intensities 9 
of PrP
res
 from Tg+Ki-Hu129M4R/M4R mice inoculated with sCJD-MM1 prions were assigned as 100 / 10 
mm² in each experiment using 3F4, POM2, or Tohoku 1 (n = 3). In the brains from 11 
Tg+Ki-Hu129M4R/M4R mice inoculated with p-dCJD prions, the mean signal intensities of 3F4-reactive 12 
PrP
res
 bands were 105 / mm² (white bars). However, the mean signal intensities of POM2/Tohoku 13 
1-reactive PrP
res
 bands were 23 / mm² (hatched bar) and 45 / mm² (grey bar), respectively. The sizes of 14 
POM2/Tohoku 1-reactive bands were smaller than those of type 1 PrP
res
 from Tg+Ki-Hu129M4R/M4R 15 
mice inoculated with non-plaque-type of dCJD (np-dCJD) prions or sCJD-MM1 prions. In addition, 16 
trace amounts of the Tohoku 2-reactive subpopulation were observed in the brains from 17 
Tg+Ki-Hu129M4R/M4R mice inoculated with p-dCJD prions, np-dCJD prions, or sCJD-MM1 prions 18 
(Fig. 5, black bars). The mean signal intensities of PrP
res
 from Ki-Hu129V/V mice inoculated with 19 
sCJD-VV2 prions were assigned as 100 / mm² in each experiment using Tohoku 2 (n = 3). Since the 20 
sizes of these Tohoku 2-reactive bands were identical to those of type 2 PrP
res
 from Ki-Hu129V/V mice 21 
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 15 
inoculated with sCJD-VV2 prions, Tohoku 2 could specifically detect type 2 PrP
res
. Meanwhile, in the 1 
transmission of p-dCJD prions to Ki-Hu129V/V mice, POM2/Tohoku 1-reactive subpopulations were 2 
decreased, whereas the Tohoku 2 reactive-subpopulation predominated. In the brains from 3 
Ki-Hu129V/V mice inoculated with p-dCJD prions, the mean signal intensities of 3F4, POM2, and 4 
Tohoku 1-reactive PrP
res
 bands were 65 / mm² (white bars), 12 / mm² (hatched bar), and 13 / mm² (grey 5 
bar), respectively, whereas the mean signal intensities of Tohoku 2-reactive PrP
res
 bands were 45 / mm² 6 
(black bar). Thus, the changes in PrP
res
 subpopulation observed in this traceback study of p-dCJD prions 7 
were identical to those observed in the traceback study of MM[VV2]2
Sh+ 
prions. 8 
 9 
DISCUSSION 10 
In order to protect humans and animals from infectious diseases, it is often crucial to determine the origin 11 
of those isolates that may lie at the origin of epidemics. In the case of conventional pathogens, this is 12 
relatively simple and primarily involves the sequencing of pathogen-associated nucleic acids. Because 13 
prions lack informational nucleic acids, however, the unambiguous assignment of a given infection to a 14 
specific source is very often impossible. Therefore, methods aimed at characterizing stable prion 15 
properties after passaging through hosts would be extremely valuable.  16 
  Here we demonstrate the first direct evidence of traceback in prion infection. Ki-Hu129V/V mice 17 
were highly susceptible to the Tg+Ki-Hu129M/M mouse-passaged sCJD-VV2 prions (MM[VV2]2
Sh+
 18 
prions) despite cross-sequence transmission (Fig. 6). In addition, MM[VV2]2
Sh+
 prions and sCJD-VV2 19 
prions exhibited similar neuropathology and the identical PrP
res
 type when inoculated into Ki-Hu129V/V 20 
mice, i.e., the altered disease phenotypes and unusual PrP
res
 type of MM[VV2]2
Sh+
 prions reverted to 21 
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 16 
those of the parental sCJD-VV2 prions. Furthermore, we generated for the first time type 2 1 
PrP
res
-specific polyclonal antibody Tohoku 2 in addition to type 1 PrP
res
-specific polyclonal antibody 2 
Tohoku 1. These PrP
res
 type-specific antibodies revealed that drastic changes in the PrP
res
 subpopulations 3 
underlie the traceback phenomenon. 4 
  The present study clearly shows that traceback studies can be a reliable tool to identify the origin of 5 
prions if atypical prion strains emerge through cross-sequence transmission. Although the numbers of 6 
animals and human brain inocula used for the transmission were limited in the present study, we 7 
demonstrated experimentally the traceback phenomenon: Ki-Hu129V/V mice were highly susceptible 8 
to MM[VV2]2
Sh+
 prions that originated from sCJD-VV2 prions. In the cross-sequence transmission of 9 
sCJD-VV2 prions to Tg+Ki-Hu129M/M mice, POM2/Tohoku 1-reactive subpopulations were 10 
increased, whereas the Tohoku 2 reactive-subpopulation was decreased. By contrast, the altered 11 
proportion of PrP
res
 subpopulations reverted to the original proportion through the traceback transmission 12 
to Ki-Hu129V/V mice. Similar changes in the PrP
res
 subpopulations were observed in the traceback 13 
transmission of p-dCJD prions to Ki-Hu129V/V mice. Therefore, the present study shows again that 14 
p-dCJD could be caused by cross-sequence transmission of sCJD-VV2 prions to individuals with the 15 
129M/M genotype. 16 
  The drastic changes in the PrP
res
 subpopulations can be the molecular basis of the traceback 17 
phenomena. We suppose that the subpopulation change observed in the cross-sequence transmission is 18 
due to adaptation and/or a selection process (3, 20), which requires a relatively long incubation period. 19 
By contrast, the subpopulation change observed in the traceback transmission might be due to 20 
reemergence of the parental prions. Since the emerging prion strain generated by the cross-sequence 21 
 at Universitaet Zuerich on January 28, 2010 
jvi.asm.org
D
ow
nloaded from
 
 17 
transmission retains the memory of the parental prions within its conformational properties or repertoire 1 
of PrP
Sc
 subpopulations, the parental PrP
Sc
 subpopulation reemerges and becomes predominant if the 2 
emerging prion strain is transmitted to the original host. Therefore, the incubation period can be 3 
shortened, and the altered disease phenotypes revert to the original ones in traceback transmission. 4 
  Unexpectedly, type 2 PrP
res
-specific antibody Tohoku 2 revealed that trace amounts of type 2 PrP
res
 5 
coexisted with type 1 PrP
res
 in the brain of a sCJD-MM1 patient. In addition, PrP-humanized mice with 6 
the 129M/M genotype inoculated with sCJD-MM1 prions could produce trace amounts of type 2 PrP
res
 7 
in addition to type 1 PrP
res
. The additional type 2 PrP
res
 was detected in Tg+Ki-Hu129M4R/M4R but not in 8 
Ki-Hu129M/M mice. Since Tg+Ki-Hu129M4R/M4R mice express human PrP with 4 octapeptide repeats 9 
at 9.8x the level observed in Ki-Hu129M/M mice, these differences might account for the subtle change. 10 
Further large-scale studies are needed to determine whether an additional type 2 PrP
res
 can be detected by 11 
Tohoku 2 in other human CJD cases formerly classified as type 1. 12 
  The present study raises the possibility that co-occurrence of multiple PrP
res
 subpopulations in the 13 
same brain might be a general phenomenon. Both type 1 and type 2 PrP
res
 can be detected in the same 14 
brain in 35% of sCJD patients examined (19, 24). By type 1 PrP
res
-specific antibodies, the minority type 15 
1 subpopulation can be detected with type 2 in all sCJD patients or variant CJD patients formerly 16 
classified as type 2 (21, 28). In accord with these reports, small amounts of type 1 (and the 17 
intermediate-sized) PrP
res
 were detected by type 1 PrP
res
-specific antibodies in Ki-Hu129V/V mice 18 
inoculated with sCJD-VV2 prions in the present our study. In addition, trace amounts of type 2 PrP
res
 19 
were detected by type 2 PrP
res
-specific antibody in the sCJD-MM1 case or Tg+Ki-Hu129M4R/M4R mice 20 
inoculated with sCJD-MM1 prions. These findings are in line with a report that diverse PrP
res
 fragments 21 
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 18 
can be detected by N-terminal amino acid sequencing in the same brain even though only a single PrP
res
 1 
type is detected by conventional western blot analysis (18). Since the conventional western blot analysis 2 
using antibodies that react with all PrP
res
 types failed to detect type 1 PrP
res
 unless type 1 PrP
res
 3 
represented more than 30-40% of total PrP
res
 in experimentally mixed type 1 + 2 brain samples, the 4 
co-occurrence of multiple PrP
res
 subpopulations might be underestimated (21, 28). Therefore, the “type” 5 
of PrP
Sc
 determined by the conventional typing system might merely represent the predominant PrP
res
 6 
subpopulation among multiple subpopulations. 7 
  However, the biological importance of the minority PrP
res
 subpopulation detected by the PrP
res
 8 
type-specific antibodies or by N-terminal amino acid sequencing remains to be determined. Insufficient 9 
proteinase K-digestion can generate type 1 specific antibody-reactive PrP bands in brain samples from 10 
sCJD or vCJD patients classified as type 2 (14). Otherwise, the size of the PrP
res
 fragment might not 11 
always reflect the conformation of PrP
Sc
, e.g., the minority MM1 PrP
res
 subpopulation detected in 12 
sCJD-MM2 patients might differ from the genuine MM1 PrP
res
 of sCJD-MM1 patients. It remains 13 
unknown whether the minority PrP
res
 subpopulation has infectivity and pathogenicity to cause prion 14 
disease. A concise and attractive explanation would be that the proportion of PrP
Sc
 subpopulations in the 15 
brain determines the disease phenotype, transmissibility, and the type of PrP
Sc
 determined by the 16 
conventional typing system, but further studies are needed to elucidate why multiple PrP
res
 17 
subpopulations can be detected in the same brain. Therefore, the significance of the conventional 18 
molecular typing system using antibodies that react with all PrP
res
 types is likely to continue to be used in 19 
the classification of sCJD.
 
20 
  In conclusion, we verified experimentally that traceback studies can be a reliable tool to identify the 21 
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 19 
origin of prions. The present study shows that the changes in PrP
res
 subpopulations correlate with the 1 
changes in prion strain-specific properties, e.g., transmissibility and disease phenotypes, in the traceback 2 
transmission. Hereafter, the proportion of PrP
res
 subpopulations in human CJD cases should be analyzed 3 
quantitatively using PrP
res
 type-specific antibodies, Tohoku 1 and Tohoku 2.4 
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FIGURE LEGENDS 1 
Fig. 1  The changes in neuropathology through cross-sequence transmission and traceback 2 
transmission. Immunohistochemical analysis of PrP
Sc
 in the brains from PrP-humanized mice 3 
inoculated with sCJD-VV2 prions or Tg+Ki-Hu129M/M mouse-passaged sCJD-VV2 prions 4 
(MM[VV2]2
Sh+
 prions: host genotype [inoculated prions] type of generated PrP
res
). Tg+Ki-Hu129M/M 5 
mice inoculated with sCJD-VV2 prions or Ki-Hu129M/M mice inoculated with MM[VV2]2
Sh+
 prions 6 
showed prominent plaque-type PrP deposits throughout the cerebral grey matter. By contrast, 7 
plaque-type PrP deposits were restricted to within the white matter in the brains from Ki-Hu129V/V 8 
mice inoculated with sCJD-VV2 prions or MM[VV2]2
Sh+
 prions. G: grey matter. W: white matter. 9 
 10 
Fig. 2  Epitope mapping of polyclonal antibody Tohoku 1. (A) GST-fusion C-terminally truncated 11 
human PrP fragments were probed with PrP-N, POM2, or Tohoku 1. POM2 (21) reacted with all PrP 12 
fragments. By contrast, Tohoku 1 reacted with PrP fragments 23-94, 23-95, and 23-96. In addition, weak 13 
reactivity to PrP fragments 23-89, 23-90, 23-91, 23-92, and 23-93 was also observed. (B) GST-fusion 14 
N-terminally truncated human PrP fragments were probed with 3F4, PrP-C, POM2, or Tohoku 1. 15 
POM2 reacted only with PrP fragment 82-230. Tohoku 1 reacted with PrP fragments 82-230, 84-230, 16 
86-230, 88-230, and 90-230. PrP fragment 97-230 corresponding to proteinase K-digested type 2 PrP
res
 17 
fragment was not detected by Tohoku 1 or POM2. Low molecular weight bands lacking the PrP-C 18 
epitope should be degradation products. 19 
 20 
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 25 
Fig. 3  Characterization of polyclonal antibody Tohoku 2 by peptide ELISA. Tohoku 2 1 
specifically reacted with a synthetic peptide corresponding to human PrP 97-103 (■), but not with 2 
peptide 93-103 (●). Control wells were coated with 0.1% BSA (▲). 3 
 4 
Fig. 4  Characterization of PrP
res
 using PrP
res
 type-specific antibodies. (A) The epitopes for type 1 5 
PrP
res
-specific polyclonal antibody Tohoku 1 or type 2 PrP
res
-specific polyclonal antibody Tohoku 2. 6 
POM2 also specifically detects type 1 PrP
res
 (21). 3F4 detects all types of PrP
res
. (B) Characterization of 7 
the human brain inocula used for the transmission studies. Western blot analysis using POM2 and 8 
Tohoku 1 revealed that the sCJD-VV2 brain contained minority subpopulations that could be detected 9 
by type 1 PrP
res
-specific antibodies, as reported previously (21, 28). Meanwhile, using type 2 10 
PrP
res
-specific antibody Tohoku 2, the minority type 2 PrP
res
 subpopulation could be detected even in the 11 
sCJD-MM1 brain. The mean signal intensities of PrP
res
 in the sCJD-MM1 brain were assigned as 100 / 12 
mm² in each experiment using 3F4 (white bars), POM2 (hatched bars), or Tohoku 1 (grey bars). The 13 
mean signal intensities of PrP
res
 in the sCJD-VV2 brain were assigned as 100 / mm² in each experiment 14 
using Tohoku 2. The signal intensities of PrP
res
 are expressed as mean ± SEM (n = 3). (C) Western blot 15 
analysis using PrP
res
 type-specific antibodies revealed that drastic changes in the PrP
res
 subpopulations 16 
underlie the traceback phenomenon. In the cross-sequence transmission of sCJD-VV2 prions to 17 
Tg+Ki-Hu129M/M mice, POM2/Tohoku 1-reactive subpopulations were increased, whereas the 18 
Tohoku 2 reactive-subpopulation was decreased. Conversely, in the traceback transmission of 19 
MM[VV2]2
Sh+
 prions to Ki-Hu129V/V mice, POM2/Tohoku 1-reactive subpopulations were decreased, 20 
whereas the Tohoku 2 reactive-subpopulation predominated. The signal intensities of PrP
res
 from 21 
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 26 
Ki-Hu129M/M mice inoculated with sCJD-MM1 were assigned as 100 / mm² in each experiment using 1 
3F4 (white bars), POM2 (hatched bars), or Tohoku 1 (grey bars). The signal intensities of PrP
res
 from 2 
Ki-Hu129V/V mice inoculated with sCJD-VV2 were assigned as 100 / mm² in each experiment using 3 
Tohoku 2 (black bars). The signal intensities of PrP
res
 are expressed as mean ± SEM (n = 4). 4 
 5 
Fig. 5  Traceback study of p-dCJD prions reevaluated with PrP
res
 type-specific antibodies. In the 6 
traceback transmission of p-dCJD prions to Ki-Hu129V/V mice, POM2/Tohoku 1-reactive 7 
subpopulations were decreased, whereas the Tohoku 2 reactive-subpopulation predominated. In addition, 8 
trace amounts of the Tohoku 2-reactive subpopulation were observed in the brains from 9 
Tg+Ki-Hu129M4R/M4R mice inoculated with p-dCJD prions, np-dCJD prions, or sCJD-MM1 prions. 10 
The signal intensities of PrP
res
 from Tg+Ki-Hu129M4R/M4R mice inoculated with sCJD-MM1 were 11 
assigned as 100 / mm² in each experiment using 3F4 (white bars), POM2 (hatched bars), or Tohoku 1 12 
(grey bars). The signal intensities of PrP
res
 from Ki-Hu129V/V mice inoculated with sCJD-VV2 were 13 
assigned as 100 / mm² in each experiment using Tohoku 2 (black bars). The signal intensities of PrP
res
 14 
are expressed as mean ± SEM (n = 3). 15 
 16 
Fig. 6  Diagram of the traceback studies. The cross-sequence transmission of sCJD-VV2 prions to 17 
Tg+Ki-Hu129M/M mice generated a new prion strain (MM[VV2]2
Sh+
 prions) with altered 18 
conformational properties and disease phenotypes after a long incubation period. In the secondary 19 
transmission, Ki-Hu129V/V mice were highly susceptible to these MM[VV2]2
Sh+
 prions despite 20 
cross-sequence transmission. Furthermore, the altered conformational properties and disease phenotypes 21 
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reverted to the original ones. If atypical prion strains emerge through cross-sequence transmission, 1 
traceback studies can be a reliable tool to identify the origin of prions. 2 
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for C-terminally truncated fragments
BamH I -23 5'-GGATCCAAGAAGCGCCCGAAGCCTGGAGGA-3'
and
89-Xho I 5'-CTCGAGTCACCAGCCACCACCATGAGGCTG-3'
90-Xho I 5'-CTCGAGTCAACCCCAGCCACCACCATGAGG-3'
91-Xho I 5'-CTCGAGTCATTGACCCCAGCCACCACCATG-3'
92-Xho I 5'-CTCGAGTCATCCTTGACCCCAGCCACCACC-3'
93-Xho I 5'-CTCGAGTCAACCTCCTTGACCCCAGCCACC-3'
94-Xho I 5'-CTCGAGTCAGCCACCTCCTTGACCCCAGCC-3'
95-Xho I 5'-CTCGAGTCAGGTGCCACCTCCTTGACCCCA-3'
96-Xho I 5'-CTCGAGTCAGTGGGTGCCACCTCCTTGACC-3'
for N-terminally truncated fragments
BamH I -82 5'-CGTGGATCCGGACAGCCTCATGGTGGTGGCTGG-3'
BamH I -84 5'-CGTGGATCCCCTCATGGTGGTGGCTGGGGTCAA-3'
BamH I -86 5'-CGTGGATCCGGTGGTGGCTGGGGTCAAGGAGGT-3'
BamH I -88 5'-CGTGGATCCGGCTGGGGTCAAGGAGGTGGCACC-3'
BamH I -90 5'-CGTGGATCCGGTCAAGGAGGTGGCACCCACAGT-3'
BamH I -92 5'-CGTGGATCCGGAGGTGGCACCCACAGTCAGTGG-3'
BamH I -94 5'-CGTGGATCCGGCACCCACAGTCAGTGGAACAAG-3'
BamH I -97 5'-CGTGGATCCAGTCAGTGGAACAAGCCGAGTAAG-3'
and
230-Xho I 5'-CCGCTCGAGTCACGATCCTCTCTGGTAATAGGCCTG-3'
Table 1   Primers used for the amplification of truncated human PrP gene fragments
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Tg+Ki-Hu129M/M Ki-Hu129M/M Ki-Hu129V/V
Inoculum (1.2X)
b
(1X) (1X)
sCJD-MM1 (H3) 429 ± 6   (6/6) 467 ± 24  (8/8) 774 ± 32  (6/6)
sCJD-VV2 (AK) 723 ± 79  (4/4) 633 ± 49  (6/6) 312 ± 7   (4/4)
MM[VV2 ]2
sh+
N.D.
c
685 ± 17  (6/6) 309 ± 3   (7/7)
b
 The expression levels of human PrP in the brains.
a
 n , number of diseased animals; n
0
, number of inoculated animals.
c
 N.D., not done.
Incubation period in days ± SEM  (n/n
0
)
a
Table 2   Transmission of sCJD prions to humanized mice with 129M/M or 129V/V
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